Date: 2017-01-04
Type of information: Collaboration agreement
Compound:
Company: Boehringer Ingelheim (Germany) leadXpro (Switzerland)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On January 4, 2017, Boehringer Ingelheim and leadXpro announced a collaboration to enter a partnership to enable structure based drug discovery and the use of biophysical methods for the advance projects for challenging membrane protein drug targets. Integral membrane proteins are responsible for key signaling and metabolic mechanisms in humans and are excellent drug targets. leadXpro has deep expertise in protein generation, biophysical and structure-based methods including serial crystallography and cryo-electron microscopy (cryo-EM), and applies these advanced techniques to the discovery and optimisation of innovative lead compounds targeting membrane proteins, such as GPCRs, ion channels and transporters.
In the collaboration, Boehringer Ingelheim and leadXpro AG will combine their expertise in membrane protein generation, crystallization and X-ray structure analysis to enable structure based drug discovery of novel lead molecules. The collaboration will include the use of leadXpro expertise in serial crystallography done at synchrotron and free electron laser to improve diffraction and enable structure determination.
Financial terms:
Latest news:
